IP Library Granted Patent US 7,803,395
Granted Patent B2
US 7,803,395 · App. 10/848,624 · Granted Sep 28, 2010

Reticulated elastomeric matrices, their manufacture and use in implantable devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,395
App. No.
10/848,624
Granted
Sep 28, 2010
Kind
B2
Abstract

This invention relates to biodurable, reticulated elastomeric matrices that are resiliently-compressible, their manufacture and uses including uses for implantable devices into or for topical treatment of patients, such as humans and other animals, for therapeutic, nutritional, or other useful purposes.

Claims (31)

1. An implantable device for promoting tissue ingrowth therein comprising:

a reticulated, resiliently-compressible, elastomeric matrix comprising a continuous network of solid structures defining a void space therein, wherein said void space comprises a plurality of interconnected pores forming a continuous network of intercommunicating passageways extending from an interior portion to an exterior surface of said matrix,

wherein said matrix comprises a biocompatible, cross-linked polycarbonate polyurethane-urea formed by a reaction of a mixture comprising:

(i) a polycarbonate polyol, and

(ii) an isocyanate component comprising at least about 5% by weight of said isocyanate component of 2,4′-diphenylmethane diisocyanate, and

wherein said matrix is substantially free of isocyanurate linkages.

2. The device according to claim 1 , wherein said mixture further comprises glycerol.

3. The device according to claim 2 , wherein said polycarbonate polyurethane-urea comprises crosslinks by said glycerol.

4. The implantable device of claim 1 , wherein an average number of isocyanate groups per molecule in said isocyanate component is greater than 2.

5. The implantable device of claim 4 , wherein said average number of isocyanate groups per molecule in said isocyanate component is about 2.33 or greater.

6. The device according to claim 1 , wherein said plurality of pores have an average diameter or other largest transverse dimension of at least about 20 μm.

7. The device according to claim 6 , wherein said plurality of pores have an average diameter or other largest transverse dimension of at least about 50 μm.

8. The device according to claim 7 , wherein said plurality of pores have an average diameter or other largest transverse dimension of at least about 150 μm.

9. The device according to claim 8 , wherein said plurality of pores have an average diameter or other largest transverse dimension of at least about 250 μm.

10. The device according to claim 1 , wherein said isocyanate component comprises from about 5% to about 50% by weight of said isocyanate component of 2,4′-diphenylmethane diisocyanate.

11. The device according to claim 10 , wherein said isocyanate component comprises from about 5% to about 40% by weight of said isocyanate component of 2,4′-diphenylmethane diisocyanate.

12. The device according to claim 11 , wherein said isocyanate component comprises from about 5% to about 35% by weight of said isocyanate component of 2,4′-diphenylmethane diisocyanate.

13. The device according to claim 1 , wherein said isocyanate component further comprises 4,4′-diphenylmethane diisocyanate.

14. The device according to claim 1 , wherein said isocyanate component consists of: (a) at least about 5% by weight of said isocyanate component of 2,4′-diphenylmethane diisocyanate, and (b) 4,4′-diphenylmethane diisocyanate.

15. The device according to claim 1 , wherein said matrix is free of isocyanurate linkages.

16. The device according to claim 1 , wherein said matrix is substantially free of allophanate and biuret linkages.

17. The device according to claim 16 , wherein said matrix is free of allophanate and biuret linkages.

18. The device according to claim 1 , wherein said polycarbonate polyol comprises a polycarbonate diol.

19. The device according to claim 1 , wherein said void space comprises from about 70% to about 99% of the volume of said matrix.

20. The device according to claim 19 wherein said void space comprises from about 80% to about 98% of the volume of said matrix.

21. The device according to claim 20 , wherein said void space comprises from about 90% to about 98% of the volume of said matrix.

22. The device according to claim 1 , wherein said isocyanate component has an isocyanate index from about 0.9 to about 1.02.

23. The device according to claim 22 , wherein said isocyanate component has an isocyanate index from about 0.9 to about 1.0.

24. The device according to claim 1 , wherein said matrix is stable for at least 29 days in a biological environment.

25. The device according to claim 1 , wherein said matrix is stable for at least six months in a biological environment.

26. The device according to claim 1 , wherein said mixture comprises from about 10 to about 90 parts by weight of said isocyanate component per 100 parts by weight of said polycarbonate polyol.

Assignments (3)
CHANGE OF ASSIGNEE ADDRESS Recorded Sep 12, 2025
From: DSM IP ASSETS B.V.
To: DSM IP ASSETS B.V.
Reel/Frame 072873/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2021
From: BIOMERIX CORPORATION
To: DSM SOMERSET ACQUISITION COMPANY, INC.,
Reel/Frame 056367/0771 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2021
From: DSM SOMERSET ACQUISITION COMPANY, INC.,
To: DSM IP ASSETS B.V.
Reel/Frame 056362/0767 →